IPA is focused on the next generation of antibody discovery, to deliver therapeutically relevant antibodies, in a short period of time, with high probability of succeeding to clinical trials. With over 30 years of experience in the custom antibody business, we have completed roughly 4000 projects for hundreds of clients across the globe, including a majority of the top 20 largest pharmaceutical companies.

Our discovery and development are conducted in Utrecht and Oss, the Netherlands (IPA Europe), and Victoria, British Columbia (IPA Canada) with headquarters located in Fargo, North Dakota. We operate multi-nationally to offer a continuum of antibody services, transforming the face of therapeutic discovery, by decreasing turnaround time and risk, and promoting clinical success.

We are comprised of experienced research and development scientists that encompass a wide range of distinctive competencies, including innovative technologies required in the production of monoclonal and polyclonal antibodies. We pride ourselves on our high customer satisfaction and our clients have grown accustomed to receiving very thorough and professional service. We customize your project to generate antibodies that meet your specific needs.

Hub of biotherapeutic intelligence
Uniting human and machine learning with the best combination of wet lab + in silico platforms, technologies, and people to conquer deadly and debilitating diseases.

Proven history of excellence
Trusted track record of scientific rigor and robust outcomes with diverse candidate pools and libraries…

Dedicated to transformative technology
IPA builds on reputation by delivering a dynamic new approach to biological intelligence that translates into meaningful knowledge…

Extension of your lab
IPA is proud of high customer satisfaction built on trust in delivering customized programs that succeed in solving complex target challenges…

Function-First focus
Proficiency in identifying clinically-relevant antibodies.

Licensing and partnership
With subsidiary partner Talem, access a VAULT of next-generation,?fully-human antibody programs to streamline your path to the clinic…

Syngeneic Cell Line